🚨📝 A pragmatic guide for management of adverse events associated with lorlatinib
Link here 👉lungcancerjournal.info/article/S0169-…

#LCSM ALK Positive

Outcomes with chemo-immunotherapy by #KRAS , STK11, and KEAP1 across PDL1 strata Lung Cancer Journal. KRAS mt enriched in PDL1 high but KRAS with co-mutations in STK11 and KEAP1 enriched in PDL1 negative. Poor OS in KRAS mt with PDL1 0% driven by STK11/KEAP1.

lungcancerjournal.info/article/S0169-…

Current Trial Report on the TARGET trial

TARGET is a phase II, open-label, single-arm study of 5-year adjuvant #osimertinib in completely resected EGFR-mutated stage II to IIIB NSCLC

Primary endpoint: investigator-assessed DFS at 5 years

More: bit.ly/46P0VcO

See this month’s highlights from the ESMO - Eur. Oncology portfolio. Featured content from Annals of Oncology, ESMO Open, ESMO IOTECH, The Breast Online, Lung Cancer Journal, Cancer Treatment Reviews and Clinical Lymphoma Myeloma and Leukemia spkl.io/60134dyVR

Happy to see our work on KL-6/MUC1 in pleural meso now out in Lung Cancer Journal:
➤ KL-6 lvls in pleural eff were diagnostic in 2 indep cohorts of pts with pleural meso.
➤⬆️KL-6 lvls and ⬆️MUC1 mRNA expression were associated with⬆️patient outcome.
👉lungcancerjournal.info/article/S0169-…

💡 #LCSM a new review by Patrick Forde and colleagues, not to be missed!! Neoadjuvant immunotherapy in NSCLC!!! 🚨
lungcancerjournal.info/action/consume…

🆕Just out in Lung Cancer Journal this interesting editorial by Jarushka Naidoo & . Francesco Cortiula discussing the role of neoadjuvant Osimertinib in resectable NSCLC, harbouring EGFR mutations #LCSM
Here the link: lungcancerjournal.info/article/S0169-…

See this month’s highlights from the ESMO - Eur. Oncology portfolio. Featured content from Annals of Oncology, ESMO Open, @ESMO_IOTECH, The Breast Online, Lung Cancer Journal, Cancer Treatment Reviews and Clinical Lymphoma Myeloma and Leukemia spkl.io/60114dyyV

🚨🆕 Just out in Lung Cancer Journal this review by Mariana Brandao et al, discussing “Systemic treatment & radiotherapy for pts with NSCLC & #HIV infection” #LCSM
Find it here 🔗lungcancerjournal.info/article/S0169-…

The European Lung Cancer Congress is ready to start in a few of days

*Official hashtag: #ELCC23 👈🏻

🚨just out in Lung Cancer Journal this important review lead by Martin Reck discussing the role of anti-angiogenic agents for the treatment of resistant NSCLC: rationale, recent updated and perspectives #LCSM 🔗 sciencedirect.com/science/articl…

TROP2 expression and SN38 antitumor activity in malignant pleural #meso thelioma cells provide a rationale for antibody-drug conjugate therapy
#LCMS #meso

lungcancerjournal.info/article/S0169-…

Age-period-cohort effect on lung cancer mortality in Spain, 1982-2021
#LCSM 🇪🇸

lungcancerjournal.info/article/S0169-…

🚨just out in Lung Cancer Journal

MET Alterations in Advanced NSCLC
METCrusaders #LCSM

lungcancerjournal.info/article/S0169-…

Have you registered for #BTOG23 yet? Our fantastic programme of expert speakers is available on our website. Join us in Belfast for this event that's not to be missed by anyone working in the field of #LungCancer ow.ly/uY9S50MVp0k

🆕🗞️Out in the Lung Cancer Journal an excellent review investigating *Primary endpoints to assess the efficacy of novel therapeutic approaches in EGFR-mutated, surgically resectable NSCLC #LCSM
lungcancerjournal.info/article/S0169-…

An excellent manuscript on ALK-positive NSCLC with brain metastases #LCSM . Read it here 👇

New ESMO Guideline: Oncogene-Addicted #mNSCLC . Developed due to rapid advances in biomarker identification & targeted therapies; updated recommendations & tx algorithms on new & clinically relevant biomarker identification, targeting & adv disease managemt
ow.ly/uV7X50MyPeA

💡🔥Out today, the Oncogene-addicted metastatic NSCLC ESMO Guideline. A significant effort to improve the management of patients w/ #lungcancer harbouring 🔟 different gene alterations! This is an amazing manuscript & I am glad to be a part of it #LCSM
sciencedirect.com/science/articl…

💥🔥just out in Annals of Oncology, the NEW ESMO - Eur. Oncology guideline for non-oncogene addicted metastatic NSCLC #LCSM ‼️

Honoured to be part of this important document (waiting for oncogene addicted one), lead by Lizza Hendriks & Martin Reck

annalsofoncology.org/article/S0923-…